ARR-217 / ArriVent, Lepu Med - LARVOL DELTA

MRG007, a cadherin 17-targeted, glycan-linked, exatecan-based antibody-drug conjugate, demonstrated potent anti-tumor activity and a good safety profile in preclinical studies (AACR 2025) - "Overall, the preclinical study results suggest that MRG007 is a differentiated and potent ADC drug candidate for the treatment of CDH17-expressing cancers in clinical trials."

Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • CDH17

ArriVent BioPharma Reports Full Year 2024 Financial Results (GlobeNewswire) - "Upcoming Milestones - EGFR PACC plans. Data from the FURTHER Phase 1b (NCT05364043) trial continues to mature for first-line firmonertinib monotherapy in NSCLC patients with EGFR PACC mutations. ArriVent expects to provide an update on our plans to develop firmonertinib in EGFR PACC mutant NSCLC in the first half of 2025. First IND Filing for ADC Program. ArriVent and its partner, Lepu BioPharma, plan to file the first IND for ARR-217 in the first half of 2025. Top-line pivotal Phase 3 data. Firmonertinib has reached its target enrollment in the FURVENT study. ArriVent anticipates having top-line data in 2025 and expects to provide an update on timing of the top-line Phase 3 data release in Q2 2025."

IND • P1 data • P3 data: top line • Non Small Cell Lung Cancer

ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers (GlobeNewswire) - "ArriVent BioPharma...announced that it has entered into an exclusive license agreement with Lepu Biopharma...for MRG007, an antibody-drug conjugate (ADC) that can target several gastrointestinal (GI) cancers. Under the terms of the agreement, ArriVent obtains the exclusive rights to develop and commercialize MRG007 worldwide outside of Greater China which includes mainland China, Hong Kong, Macau and Taiwan....The first IND submission is planned for the first half of 2025 with an initial clinical development focus in CRC, pancreatic and other GI cancers."

IND • Licensing / partnership • Colorectal Cancer • Pancreatic Cancer